UPDATE: Abbvie (ABBV) Dermatologist Study Puts Skyrizi on Par With Enbrel, PT to $81 at Piper Jaffray
Tweet Send to a Friend
(Updated - September 4, 2019 10:26 AM EDT)
Piper Jaffray analyst Christopher Raymond raised the price target on Abbvie ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper Jaffray analyst Christopher Raymond raised the price target on Abbvie ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
